Compile Data Set for Download or QSAR
Report error Found 120 Enz. Inhib. hit(s) with all data for entry = 1714
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336788( (2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5R)-5-((4-(...)
Affinity DataIC50: 4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336789((2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5R)-5-((4-(f...)
Affinity DataIC50: 8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336766((2-(2H-1,2,3-triazol-2- yl)phenyl)((2R,5R)-2- meth...)
Affinity DataIC50: 8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336784(4-Methoxy-3-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-...)
Affinity DataIC50: 9.70nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336790((2-(2H-1,2,3-Triazol-2-yl)thiophen-3-yl)((2R,5R)-5...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336793(4-(difluoromethoxy)- 2-{[(3R,6R)-6- methyl-1-{[2-(...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336752(2-({(3R,6R)-1-[(2- cyclopropylphenyl) carbonyl]-6-...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336792(1-(2-{[(2R,5R)- 5-{[4- (difluoromethoxy) pyridin-2...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336795(4-methoxy-2- {[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-t...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336765((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((4-(2...)
Affinity DataIC50: 12nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336787(1-(4-methoxy-2- {[(3R,6R)-6- methyl-1-{[2-(2H- 1,2...)
Affinity DataIC50: 12.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50084395(CHEMBL3426144 | US9745284, 2)
Affinity DataIC50: 12.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336791(4-(difluoromethoxy)- 2-{[(3R,6R)- 6-methyl-1- {[4-...)
Affinity DataIC50: 13nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336751(2-{[(3R,6R)-1- {[3-fluoro-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 14.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336745(3-bromo-4-methoxy-2-{[(3R,6R)-6- methyl-1-{[2-(2H-...)
Affinity DataIC50: 14.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336747(4-(1-methylethoxy)-2-{[(3R,6R)-6-methyl-1-{[2-(2H-...)
Affinity DataIC50: 15.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336777(4-(Cyclopropyloxy)-2-{[(3R,6R)-6-methyl-1-{[2-(2H-...)
Affinity DataIC50: 15.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336748(4-methoxy-2-{[(3R,6R)-6-methyl-1-{[4-(2H-1,2,3-tri...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336743(4-Ethoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-tria...)
Affinity DataIC50: 20.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336794(((2R,5R)-5-((4-Methoxypyridin-2-yl)oxy)-2-methylpi...)
Affinity DataIC50: 21nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336796((2-(2H-1,2,3-Triazol-2-yl)thiophen-3-yl)((2R,5R)-5...)
Affinity DataIC50: 22nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336798(4-ethoxy-2-{[(3R,6R)-6- methyl-1-{[2-(2H-1,2,3- tr...)
Affinity DataIC50: 22nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336758(2-{[(3R,6R)-1- {[4-fluoro-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 22.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336749(4-(1- methylethoxy)- 2-{[(3R,6R)-6- methyl-1-{[2- ...)
Affinity DataIC50: 23nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336770(1-(2-{[(2R,5R)-5-{[4-(2,2- difluoroethoxy)pyridin-...)
Affinity DataIC50: 24nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336755(6-methoxy-3- ({(2R,5R)-5-[(4- methoxypyridin- 2-yl...)
Affinity DataIC50: 24.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336797(4-(1-methylethoxy)-2- {[(3R,6R)-6-methyl-1-{[2- (2...)
Affinity DataIC50: 25nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336801(((2R,5R)-5-(4-Ethoxypyridin-2-yloxy)-2-methylpiper...)
Affinity DataIC50: 26nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336802(2-(3-{[(2R,5R)-2- methyl-5-{[4-(2,2,2- trifluoroet...)
Affinity DataIC50: 26nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336756(2-{[(3R,6R)-1- {[2-fluoro-6-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 27nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336767(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-6-methyl-1-{[2...)
Affinity DataIC50: 29nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336781(2-(2-{[(2R,5R)-5-{[4-(2,2- difluoroethoxy)pyridin-...)
Affinity DataIC50: 33nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336769(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-6-methyl-1-({2...)
Affinity DataIC50: 34nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336754(2-({(3R,6R)-1-[(2- ethoxyphenyl) carbonyl]-6- meth...)
Affinity DataIC50: 34.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336750(4-ethoxy-2- {[(3R,6R)-6- methyl-1-{[2- (2H-tetrazo...)
Affinity DataIC50: 35.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336800(((2R,5R)-5-((4-(2,2-Difluoroethoxy)pyridin-2-yl)ox...)
Affinity DataIC50: 36nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336764(2-{[(3R,6R)-1- {[5-fluoro-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 37.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336786(4-Methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 37.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336768(2-{[(3R,6R)-6-methyl-1-{[2- (2H-tetrazol-2- yl)phe...)
Affinity DataIC50: 38nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336760(2-cyclopropyl- 6-methoxy-3- ({(2R,5R)-5-[(4- metho...)
Affinity DataIC50: 38.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336779(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50: 38.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336761(2-{[(3R,6R)-1- {[4-fluoro-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 41.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336772(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-1-{[3-fluoro-2...)
Affinity DataIC50: 42nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336775(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-6-methyl-1-{[2...)
Affinity DataIC50: 52nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336799(2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 55nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336774(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-1-{[2-fluoro-6...)
Affinity DataIC50: 56nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336776(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-6-methyl-1-{[2...)
Affinity DataIC50: 56nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336753(4-methoxy-2- {[(3R,6R)-6- methyl-1-{[2- (trifluoro...)
Affinity DataIC50: 56.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336746(4-(benzyloxy)-2-{[(3R,6R)-6- methyl-1-{[2-(2H-1,2,...)
Affinity DataIC50: 59.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM336773(4-(2,2-difluoroethoxy)-2- {[(3R,6R)-1-{[4-fluoro-2...)
Affinity DataIC50: 62nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/5/2019
Entry Details
US Patent

Displayed 1 to 50 (of 120 total ) | Next | Last >>
Jump to: